Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR

被引:28
作者
Kostopoulou, Evanthia [1 ]
Vageli, Dimitra [1 ]
Kaisaridou, Despina [2 ]
Nakou, Marianna [1 ]
Netsika, Maria [1 ]
Vladica, Natalia [2 ]
Daponte, Alexandros [3 ]
Koukoulis, George [1 ]
机构
[1] Univ Hosp Larissa, Med Sch Thessalia, Dept Pathol, Larisa, Greece
[2] Theagene Anticanc Hosp Thessaloniki, Dept Pathol, Thessaloniki, Greece
[3] Univ Hosp Larissa, Med Sch Thessalia, Dept Obstet & Gynecol, Larisa, Greece
关键词
HER-2; FISH; CISH; RT-PCR; breast carcinoma; polysomy;
D O I
10.1016/j.breast.2007.05.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The routine assessment of HER-2 expression can be affected by many immunohistological preanalyticat and analytical variables. The evaluation of non-informative HER-2 tests, because of 2(+) scores, has been addressed in studies using in situ hybridization (fluorescent in situ hybridization (FISH) or chromogenic in situ hybridization (CISH)). There are very few studies that additionally checked 2(+) cases by quantitative reverse transcription- PCR (QRT-PCR). We analyzed totally 195 breast carcinoma cases, 70 of them showing 2(+) immunoreaction, with FISH/CISH and QRTPCR. Confirmed amplification in 2(+) cases felt within the reported range (12.8% vs. 8-44%) and some of them showed lower mRNA levels indicating a genuine decrease of HER-2 protein as a mechanism for the non-informative score. In other cases, increased mRNA levels could be ascribed to HER-2 polysomy, verifying previous observations of immunohistotogically detectable HER-2 polysomy. A remarkable subset of the 2(+) cases showed "normal" mRNA levels without amplification or polysomy and technical parameters as well as heterogeneity could be incriminated. The overall concordance of QRT-PCR and FISH was 93.8%, highest than most previously reported. Yet, the tack of clear cut-off mRNA values and the challenge of sample microdissection hinder QRT-PCR from claiming the status of a gold standard test for HER-2 evaluation. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:615 / 624
页数:10
相关论文
共 77 条
[1]   ERBB2 GENE AMPLIFICATION DETECTED BY FLUORESCENT DIFFERENTIAL POLYMERASE CHAIN-REACTION IN PARAFFIN-EMBEDDED BREAST-CARCINOMA TISSUES [J].
AN, HX ;
NIEDERACHER, D ;
BECKMANN, MW ;
GOHRING, UJ ;
SCHARL, A ;
PICARD, F ;
VANROEYEN, C ;
SCHNURCH, HG ;
BENDER, HG .
INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (05) :291-297
[2]   Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer [J].
Arnould, L ;
Denoux, Y ;
MacGrogan, G ;
Penault-Llorca, F ;
Fiche, M ;
Treilleux, I ;
Mathieu, MC ;
Vincent-Salomon, A ;
Vilain, MO ;
Couturier, J .
BRITISH JOURNAL OF CANCER, 2003, 88 (10) :1587-1591
[3]   Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use [J].
Bánkfalvi, A ;
Simon, R ;
Brandt, B ;
Bürger, H ;
Vollmer, I ;
Dockhorn-Dworniczak, B ;
Lellé, RJ ;
Boecker, W .
HISTOPATHOLOGY, 2000, 37 (05) :411-419
[4]   Gene transcript assay by real-time RT-PCR in epithelial breast cancer cells selected by laser microdissection [J].
Becette, V ;
Vignaud, S ;
Régnier, C ;
Labroquère, M ;
Fourme, E ;
Menet, E ;
Bièche, I ;
Spyratos, F .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2004, 19 (02) :100-108
[5]   Prognostic value of ERBB family mRNA expression in breast carcinomas [J].
Bièche, I ;
Onody, P ;
Tozlu, S ;
Driouch, K ;
Vidaud, M ;
Lidereau, R .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (05) :758-765
[6]  
Bièche I, 1999, CLIN CHEM, V45, P1148
[7]   Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry [J].
Bilous, M ;
Morey, A ;
Armes, J ;
Cummings, M ;
Francis, G .
PATHOLOGY, 2006, 38 (02) :120-124
[8]   Current perspectives on HER2 testing:: A review of national testing guidelines [J].
Bilous, M ;
Dowsett, M ;
Hanna, W ;
Isola, J ;
Lebeau, A ;
Moreno, A ;
Penault-Llorca, F ;
Rüschoff, J ;
Tomasic, G ;
de Vijver, MV .
MODERN PATHOLOGY, 2003, 16 (02) :173-182
[9]   Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study [J].
Bilous, M ;
Ades, C ;
Armes, J ;
Bishop, J ;
Brown, R ;
Cooke, B ;
Cummings, M ;
Farshid, G ;
Field, A ;
Morey, A ;
McKenzie, P ;
Raymond, W ;
Robbins, P ;
Tan, L .
BREAST, 2003, 12 (02) :92-98
[10]   HER2 testing recommendations in Australia [J].
Bilous, M .
PATHOLOGY, 2001, 33 (04) :425-427